Table 1 Clinical characteristics, support and treatment of 154 patients with COVID-19 infection
COVID-19 patients | |
|---|---|
Demographics | N (%) |
Gender | |
Male Female | 87 (56.5) 67 (43.5) |
Age (years) | 60.0 (21.0 − 90.0) |
Systemic Arterial Hypertension | |
No Yes | 76 (49.4) 78 (50.6) |
Type 2 diabetes mellitus | |
No Yes | 104 (67.6) 50 (32.5) |
Obesity | |
No Yes | 130 (84.4) 24 (15.6) |
COPD | |
No Yes | 148 (96.1) 6 (3.9) |
Asthma | |
No Yes | 149 (96.8) 5 (3.2) |
Kidney disease | |
No Yes | 141 (91.6) 13 (8.4) |
Hepatic disease | |
No Yes | 151 (98.1) 3 (1.9) |
Cardiopathy | |
No Yes | 141 (91.6) 13 (8.4) |
Cancer | |
No Yes | 122 (79.2) 32 (20.8) |
Autoimmune disease | |
No Yes | 148 (96.1) 6 (3.9) |
Dyslipidemia | |
No Yes | 147 (95.5) 7 (4.5) |
Neurologic and psychiatric disorders | |
No Yes | 142 (92.2) 12 (7.8) |
Smoking | |
No Yes Ex | 133 (86.4) 10 (6.5) 11 (7.1) |
Alcoholic | |
No Yes Ex | 147(95.5) 3 (1.9) 4 (2.6) |
Comorbidities | |
No Yes | 18 (11.7) 136 (88.3) |
Respiratory symptoms | |
No Yes | 26 (16.9) 128 (83.1) |
ICU admission | |
No Yes | 37 (24.0) 117 (76.0) |
Oseltamivir | |
No Yes | 36 (23.4) 118 (76.6) |
Azithromycin | |
No Yes | 24 (15.6) 130 (84.4) |
Hydroxychloroquine | |
No Yes | 59 (38.3) 95 (61.7) |
Corticosteroids | |
No Yes | 39 (25.3) 115 (74.7) |
Heparin | |
No Yes | 8 (5.2) 146 (94.8) |
DVT | |
No Yes | 152 (98.7) 2 (1.3) |
Endotracheal Intubation | |
No Yes | 109 (70.8) 45 (29.2) |
Pulmonary involvement > 50% | |
No Yes No CT | 58 (37.7) 59 (38.3) 37 (24.0) |